SEARCH

SEARCH BY CITATION

References

  • 1
    Center MM, Jemal A, Lortet-Tieulent J et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 10791092
  • 2
    Brawley OW. Prostate cancer epidemiology in the United States. World J Urol 2012; 30: 195200
  • 3
    Outzen M, Brasso K, Martinussen N et al. Prostate cancer in Denmark 1978–2009 – trends in incidence and mortality. Acta Oncol 2013; 52: 831836
  • 4
    Heidenreich A, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 6171
  • 5
    Wilt TJ, Brawer MK, Jones KM et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203213
  • 6
    Choo R, Klotz L, Danjoux C et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002; 167: 16641669
  • 7
    Lees K, Durve M, Parker C. Active surveillance in prostate cancer: patient selection and triggers for intervention. Curr Opin Urol 2012; 22: 210215
  • 8
    O'Brien MF, Cronin AM, Fearn PA et al. Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively. Int J Cancer 2011; 128: 23732381
  • 9
    Thomsen FB, Roder MA, Hvarness H, Iversen P, Brasso K. Active surveillance can reduce overtreatment in patients with low-risk prostate cancer. Dan Med J 2013; 60: A4575
  • 10
    D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969974
  • 11
    Ross AE, Loeb S, Landis P et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010; 28: 28102816
  • 12
    Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005; 174: 21912196
  • 13
    Robinson D, Sandblom G, Johansson R et al. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer. Urology 2008; 72: 903907
  • 14
    Fall K, Garmo H, Andren O et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007; 99: 526532
  • 15
    Bastian PJ, Carter BH, Bjartell A et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009; 55: 13211330
  • 16
    Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126131
  • 17
    Klotz L. Active surveillance: the Canadian experience. Curr Opin Urol 2012; 22: 222230
  • 18
    Bul M, Zhu X, Valdagni R et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 2013; 63: 597603
  • 19
    Oesterling JE, Rice DC, Glenski WJ, Bergstralh EJ. Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology 1993; 42: 276282
  • 20
    Yuan JJ, Coplen DE, Petros JA et al. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol 1992; 147 (3 Pt 2): 810814
  • 21
    Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907923
  • 22
    Stamey TA, McNeal JE, Freiha FS, Redwine E. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 1988; 139: 12351241
  • 23
    Stamey TA, Kabalin JN, McNeal JE et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989; 141: 10761083
  • 24
    Choo R, Deboer G, Klotz L et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001; 50: 615620
  • 25
    Arlen PM, Bianco F, Dahut WL et al. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 2008; 179: 21812185
  • 26
    Beauval JB, Ploussard G, Soulie M et al. Pathologic findings in radical prostatectomy specimens from patients eligible for active surveillance with highly selective criteria: a multicenter study. Urology 2012; 80: 656660
  • 27
    El Hajj A, Ploussard G, de la Taille A et al. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS). BJU Int 2013; 111: 5359
  • 28
    O'Brien MF, Cronin AM, Fearn PA et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 2009; 27: 35913597
  • 29
    Maruyama S, Shinohara N, Abe T, Sazawa A, Nonomura K. Can PSA doubling time exactly predict the candidates for active surveillance in patients with low-risk prostate cancer? J Clin Oncol 2012; 30 (5 Suppl. [Februarary 10 Supplement]), abstr 65. Journal of Clinical Oncology, 2012 Genitourinary Cancers Symposium